Nefopam-d4 hydrochloride(Synonyms: Fenazoxine-d4 hydrochloride)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物,专注于信号通路和疾病研究领域。
Nefopam-d4 hydrochloride (Synonyms: Fenazoxine-d4 hydrochloride)

Nefopam-d4 (hydrochloride) 是 Nefopam (hydrochloride) 氘代物。Nefopam hydrochloride (Fenazoxine hydrochloride) 是中枢性但非阿片类缓解中度和重度疼痛。Nefopam hydrochloride 作用于体外和体内间充质细胞β-连环蛋白水平。

Nefopam-d4 hydrochloride(Synonyms: Fenazoxine-d4 hydrochloride)

Nefopam-d4 hydrochloride Chemical Structure

CAS No. : 2747915-60-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Nefopam-d4 (hydrochloride) is deuterium labeled Nefopam (hydrochloride). Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo[1][2].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

293.82

Formula

C17H16D4ClNO

CAS 号

2747915-60-0

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Kim KH, et al. Rediscovery of nefopam for the treatment of neuropathic pain. Korean J Pain. 2014 Apr;27(2):103-11.

    [3]. Baht GS, et al. Pharmacologically targeting beta-catenin for NF1 associated deficiencies in fracture repair. Bone. 2017 May;98:31-36.

    [4]. Poon R, et al. A high throughput screen identifies Nefopam as targeting cell proliferation in β-catenin driven neoplastic and reactive fibroproliferative disorders. PLoS One. 2012;7(5):e37940.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务